Reneo pulls plug on only asset after phase 2b fail, sending 70% of staff out the door and stock plummeting
Reneo Pharmaceuticals’ rare genetic disease study has missed both primary and secondary goals, prompting the California biotech to halt the development of its only asset and lay off 70% of staff.